Spartan Wealth Advisory Services LLC Purchases Shares of 5,408 Becton, Dickinson and Company $BDX

Spartan Wealth Advisory Services LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 5,408 shares of the medical instruments supplier’s stock, valued at approximately $850,000.

Several other large investors also recently made changes to their positions in the stock. Brighton Jones LLC increased its holdings in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares in the last quarter. United Bank lifted its holdings in shares of Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after purchasing an additional 993 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after buying an additional 25,022 shares during the period. Finally, NewEdge Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 34.7% during the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after buying an additional 6,058 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of recent research reports. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Piper Sandler reduced their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Bank of America decreased their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Finally, Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $180.29.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 5,188 shares of company stock worth $765,120. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.0%

BDX stock opened at $158.14 on Monday. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The stock has a market cap of $43.57 billion, a price-to-earnings ratio of 40.04, a price-to-earnings-growth ratio of 11.19 and a beta of 0.21. The company has a fifty day moving average price of $148.99 and a two-hundred day moving average price of $166.18. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.